Victoria Blaho, Ph.D., assistant professor in the Immunity and Pathogenesis Program, has received the first-ever Lina M. Obeid Award for her promising research on the biology of sphingolipids.

These targets could be key in designing treatments for advanced colon, breast and ovarian cancers.

Research pinpoints interferon stimulating genes that control SARS-CoV-2 replication.

Scientists at Sanford Burnham Prebys have shown that two existing drug candidates—JAK inhibitors and Mepron—hold potential as treatments for a deadly acute myeloid leukemia (AML) subtype that is more common in children.

The heart is the core of life, and for Ph.D. graduate student Katja Birker, it’s the foundation for the beginning of a career.

The Conrad Prebys Foundation provides $3 million to Robert Wechsler-Reya, Ph.D., and his team of researchers to advance a potential drug to treat medulloblastoma—the most common malignant brain tumor in children.

Million reflects on how a summer internship at Sanford Burnham Prebys accelerated his scientific career.

Two patients whose lives were saved by discoveries made by Hudson Freeze, Ph.D., and José Luis Millán, Ph.D., joined the scientists for a conversation about what this work means to them and how their lives have been impacted.

Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a drug candidate that blocks the uptake of glutamine, a key food source for many tumors, and slows the growth of melanoma.

In an effort to find new treatments for COVID-19 that could be made available quickly, researchers searched through FDA-approved drugs to identify candidates that may inhibit SARS-CoV-2 replication. Researchers found that a decades-old anti-leprosy drug exhibits potent antiviral activities against many coronaviruses—including SARS-CoV-2.

Scientists demonstrated for the first time that blocking “cell drinking,” or macropinocytosis, in the thick tissue surrounding a pancreatic tumor slowed tumor growth.

Scientists pointed to clofazimine, a low-cost leprosy drug first approved by the FDA in 1986, as a possible COVID-19 drug after finding promising anti-coronavirus activity in hamsters.